Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-
2. Leclaza
3. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide
1. 1903008-80-9
2. Yh-25448
3. Gns-1480
4. Yh25448
5. Gns1480
6. Jnj-73841937-aaa
7. Lazertinib [usan]
8. C-18112003-g
9. N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide
10. 4a2y23xk11
11. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide
12. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-
13. Leclaza
14. Lazertinib [inn]
15. Lazertinib [inn]
16. Lazertinib (yh25448)
17. Lazertinib [who-dd]
18. Unii-4a2y23xk11
19. Chembl4558324
20. Schembl17670400
21. Gtpl10136
22. Bcp30440
23. Ex-a1912
24. Bdbm50555575
25. S8724
26. Who 10587
27. Akos037515597
28. Ccg-270023
29. Lazertinib (yh25448,gns-1480)
30. Yh-25448;gns-1480
31. Ac-36243
32. Bs-15742
33. Compound 73 [wo2016060443a2]
34. Hy-109061
35. Cs-0032992
36. A16827
37. A903188
38. Yh-25448; Yh 25448; Yh25448; Gns-1480; Gns 1480; Gns1480
39. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide
40. N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Molecular Weight | 554.6 g/mol |
---|---|
Molecular Formula | C30H34N8O3 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 10 |
Exact Mass | 554.27538698 g/mol |
Monoisotopic Mass | 554.27538698 g/mol |
Topological Polar Surface Area | 110 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 837 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Registrant Name : Yuhan Chemical Co., Ltd.
Registration Date : 2021-01-18
Registration Number : 1791-9-ND
Manufacturer Name : Yuhan Chemical Co., Ltd.
Manufacturer Address : 402, 5-ba, Sihwa Industrial Complex, 45 Jiwon-ro, Danwon-gu, Ansan-si, Gyeonggi-do (S...
Lee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.
About the Company : Lee Fine Chem Private Limited specializes in Advanced Intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms. With a strong focus on quality and innovat...
About the Company : Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and...
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2025
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EU Approves RYBREVANT For Advanced EGFR-Mutated Lung Cancer
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
April 07, 2025
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Issues Positive Opinion for SC Rybrevant® in Advanced EGFR+ NSCLC
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
February 03, 2025
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Recommends SC Rybrevant for Advanced EGFR+ NSCLC Treatment
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
February 03, 2025
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2024
Lead Product(s) : Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Approves RYBREVANT® and LAZCLUZE® Combo for First-Line EGFR-Mutated NSCLC Treatment
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
December 30, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2024
Lead Product(s) : Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Recommends RYBREVANT® and LAZCLUZE® for EGFR-Mutated Lung Cancer
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
November 15, 2024
Details:
Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) and dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer.
Lead Product(s): Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2024
Lead Product(s) : Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dexamethasone Reduces Infusion Reactions in EGFR-Mutated NSCLC Patients On RYBREVANT®
Details : Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) and dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
October 09, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2024
Lead Product(s) : Amivantamab,Dexamethasone,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
J&J's Chemotherapy-Free Treatment for Lung Cancer Gets US Approval
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
August 20, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody evaluated with lazertinib for first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Janssen Submits Type II Extension for RYBREVANT and Lazertinib
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody evaluated with lazertinib for first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
August 02, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amivantamab BLA Submitted to FDA for EGFR-Mutated Non-Small Cell Lung Cancer
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
June 17, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of EGFR-mutated NSCLC after failure of prior therapy.
Lead Product(s): Amivantamab,Carboplatin,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2024
Lead Product(s) : Amivantamab,Carboplatin,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RYBREVANT® Plus Lazertinib Shows Longer PFS vs. Osimertinib in High-Risk NSCLC
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of EGFR-mutated NSCLC after failure of prior therapy.
Product Name : Rybrevant
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2024
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2041-08-01
US Patent Number : 11850248
Drug Substance Claim :
Drug Product Claim :
Application Number : 219008
Patent Use Code : U-3985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2041-08-01
Patent Expiration Date : 2040-05-21
US Patent Number : 11879013
Drug Substance Claim :
Drug Product Claim :
Application Number : 219008
Patent Use Code : U-3985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2040-05-21
Patent Expiration Date : 2038-04-18
US Patent Number : 11453656
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219008
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-04-18
Patent Expiration Date : 2035-10-13
US Patent Number : 9593098
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219008
Patent Use Code : U-3985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-10-13
Patent Expiration Date : 2041-04-13
US Patent Number : 12138351
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 219008
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2041-04-13
Patent Expiration Date : 2035-10-13
US Patent Number : 9593098
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219008
Patent Use Code : U-3985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-10-13
Patent Expiration Date : 2038-04-18
US Patent Number : 11453656
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219008
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-04-18
Patent Expiration Date : 2038-04-18
US Patent Number : 11981659
Drug Substance Claim :
Drug Product Claim :
Application Number : 219008
Patent Use Code : U-3985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-04-18
Patent Expiration Date : 2041-04-13
US Patent Number : 12138351
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 219008
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2041-04-13
Patent Expiration Date : 2038-04-18
US Patent Number : 11981659
Drug Substance Claim :
Drug Product Claim :
Application Number : 219008
Patent Use Code : U-3985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-04-18
ABOUT THIS PAGE
90
PharmaCompass offers a list of Lazertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lazertinib manufacturer or Lazertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lazertinib manufacturer or Lazertinib supplier.
PharmaCompass also assists you with knowing the Lazertinib API Price utilized in the formulation of products. Lazertinib API Price is not always fixed or binding as the Lazertinib Price is obtained through a variety of data sources. The Lazertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lazertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lazertinib, including repackagers and relabelers. The FDA regulates Lazertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lazertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lazertinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lazertinib supplier is an individual or a company that provides Lazertinib active pharmaceutical ingredient (API) or Lazertinib finished formulations upon request. The Lazertinib suppliers may include Lazertinib API manufacturers, exporters, distributors and traders.
click here to find a list of Lazertinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lazertinib Drug Master File in Korea (Lazertinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lazertinib. The MFDS reviews the Lazertinib KDMF as part of the drug registration process and uses the information provided in the Lazertinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lazertinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lazertinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lazertinib suppliers with KDMF on PharmaCompass.
Lazertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lazertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lazertinib GMP manufacturer or Lazertinib GMP API supplier for your needs.
A Lazertinib CoA (Certificate of Analysis) is a formal document that attests to Lazertinib's compliance with Lazertinib specifications and serves as a tool for batch-level quality control.
Lazertinib CoA mostly includes findings from lab analyses of a specific batch. For each Lazertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lazertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lazertinib EP), Lazertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lazertinib USP).